John Lee (University of California, Los Angeles)님 | 한빛사연구자 > 한빛사

University of California, Los Angeles

CV File

최종업데이트 2026.01.02.

- John Lee(University of California, Los Angeles)
Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer
- J. Clin. Invest., Jun 23 2026, e200438 | https://doi.org/10.1172/JCI200438
- 2026-06
- 한빛사논문
Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer
- Sci. Adv., Jan 02 2026, 12 (1) | https://doi.org/10.1126/sciadv.ady0041
- 2026-01
- 바이오·의료융합
- 한빛사논문
- John Lee(University of California, Los Angeles)
Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models
- Nat. Biomed. Eng., Published: 23 October 2025 | https://doi.org/10.1038/s41551-025-01508-3
- 2025-10
- 한빛사논문
- John Lee(University of Washington and Fred Hutchinson Cancer Research Center)
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
- Nat. Commun., Published: 11 April 2023 | https://doi.org/10.1038/s41467-023-37874-2
- 2023-04
- 한빛사논문
- John Lee(University of Washington and Fred Hutchinson Cancer Research Center)
[CCR Translations]BiTE-ing into prostate cancer with bispecific T cell engagers
- Clin. Cancer Res., Published first March 11, 2021 | DOI: 10.1158/1078-0432.CCR-21-0355
- 2021-03
- 한빛사논문
- John Lee(University of Washington, Fred Hutchinson Cancer Research Center)
Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer
- Clin. Cancer Res., Published first November 16, 2020 | https://doi.org/10.1158/1078-0432.CCR-20-3396
- 2020-11
- 한빛사논문

연구자 ID

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기